168 related articles for article (PubMed ID: 26205198)
1. Structural Requirements of Some 2-(1-Propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide Derivatives as Poly (ADP-Ribose) Polymerase (PARP) for the Treatment of Cancer: QSAR Approach.
Sharma MC
Interdiscip Sci; 2016 Mar; 8(1):11-22. PubMed ID: 26205198
[TBL] [Abstract][Full Text] [Related]
2. Structural requirements of some 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide derivatives as poly (ADP-ribose) polymerase (PARP) for the treatment of cancer: QSAR approach.
Sharma MC
Interdiscip Sci; 2014 Sep; ():. PubMed ID: 25183353
[TBL] [Abstract][Full Text] [Related]
3. QSAR study of 2-(1-Propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide as PARP inhibitors for treatment of cancer.
Riahi S; Pourbasheer E; Dinarvand R; Ganjali MR; Norouzi P
Chem Biol Drug Des; 2008 Dec; 72(6):575-84. PubMed ID: 19090924
[TBL] [Abstract][Full Text] [Related]
4. Discovery and SAR study of 2-(1-propylpiperidin-4-yl)-3H-imidazo[4,5-c]pyridine-7-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) for the treatment of cancer.
Zhu Q; Wang X; Hu Y; He X; Gong G; Xu Y
Bioorg Med Chem; 2015 Oct; 23(20):6551-9. PubMed ID: 26422786
[TBL] [Abstract][Full Text] [Related]
5. Molecular modeling studies on benzimidazole carboxamide derivatives as PARP-1 inhibitors using 3D-QSAR and docking.
Zeng H; Zhang H; Jang F; Zhao L; Zhang J
Chem Biol Drug Des; 2011 Sep; 78(3):333-52. PubMed ID: 21585709
[TBL] [Abstract][Full Text] [Related]
6. Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer.
Penning TD; Zhu GD; Gandhi VB; Gong J; Thomas S; Lubisch W; Grandel R; Wernet W; Park CH; Fry EH; Liu X; Shi Y; Klinghofer V; Johnson EF; Donawho CK; Frost DJ; Bontcheva-Diaz V; Bouska JJ; Olson AM; Marsh KC; Luo Y; Rosenberg SH; Giranda VL
Bioorg Med Chem; 2008 Jul; 16(14):6965-75. PubMed ID: 18541433
[TBL] [Abstract][Full Text] [Related]
7. Contrasting sirtuin and poly(ADP-ribose)polymerase activities of selected 2,4,6-trisubstituted benzimidazoles.
Yeong KY; Tan SC; Mai CW; Leong CO; Chung FF; Lee YK; Chee CF; Abdul Rahman N
Chem Biol Drug Des; 2018 Jan; 91(1):213-219. PubMed ID: 28719017
[TBL] [Abstract][Full Text] [Related]
8. Multiple receptor conformation docking, dock pose clustering and 3D QSAR studies on human poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors.
Fatima S; Jatavath MB; Bathini R; Sivan SK; Manga V
J Recept Signal Transduct Res; 2014 Oct; 34(5):417-30. PubMed ID: 25046176
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose)polymerase (PARP) inhibitors.
Chen X; Huan X; Liu Q; Wang Y; He Q; Tan C; Chen Y; Ding J; Xu Y; Miao Z; Yang C
Eur J Med Chem; 2018 Feb; 145():389-403. PubMed ID: 29335205
[TBL] [Abstract][Full Text] [Related]
10. A novel and orally active poly(ADP-ribose) polymerase inhibitor, KR-33889 [2-[methoxycarbonyl(4-methoxyphenyl) methylsulfanyl]-1H-benzimidazole-4-carboxylic acid amide], attenuates injury in in vitro model of cell death and in vivo model of cardiac ischemia.
Oh KS; Lee S; Yi KY; Seo HW; Koo HN; Lee BH
J Pharmacol Exp Ther; 2009 Jan; 328(1):10-8. PubMed ID: 18836068
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 2-(1-(3-(4-Chloroxyphenyl)-3-oxo- propyl)pyrrolidine-3-yl)-1
Min R; Wu W; Wang M; Tang L; Chen D; Zhao H; Zhang C; Jiang Y
Molecules; 2019 May; 24(10):. PubMed ID: 31108884
[TBL] [Abstract][Full Text] [Related]
12. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
Thorsell AG; Ekblad T; Karlberg T; Löw M; Pinto AF; Trésaugues L; Moche M; Cohen MS; Schüler H
J Med Chem; 2017 Feb; 60(4):1262-1271. PubMed ID: 28001384
[TBL] [Abstract][Full Text] [Related]
13. Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase.
White AW; Almassy R; Calvert AH; Curtin NJ; Griffin RJ; Hostomsky Z; Maegley K; Newell DR; Srinivasan S; Golding BT
J Med Chem; 2000 Nov; 43(22):4084-97. PubMed ID: 11063605
[TBL] [Abstract][Full Text] [Related]
14. Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor.
Penning TD; Zhu GD; Gong J; Thomas S; Gandhi VB; Liu X; Shi Y; Klinghofer V; Johnson EF; Park CH; Fry EH; Donawho CK; Frost DJ; Buchanan FG; Bukofzer GT; Rodriguez LE; Bontcheva-Diaz V; Bouska JJ; Osterling DJ; Olson AM; Marsh KC; Luo Y; Giranda VL
J Med Chem; 2010 Apr; 53(8):3142-53. PubMed ID: 20337371
[TBL] [Abstract][Full Text] [Related]
15. Design of potential anti-tumor PARP-1 inhibitors by QSAR and molecular modeling studies.
Abbasi-Radmoghaddam Z; Riahi S; Gharaghani S; Mohammadi-Khanaposhtanai M
Mol Divers; 2021 Feb; 25(1):263-277. PubMed ID: 32140890
[TBL] [Abstract][Full Text] [Related]
16. Synergistic cytotoxicity of the poly (ADP-ribose) polymerase inhibitor ABT-888 and temozolomide in dual-drug targeted magnetic nanoparticles.
Muñoz-Gámez JA; López Viota J; Barrientos A; Carazo Á; Sanjuán-Nuñez L; Quiles-Perez R; Muñoz-de-Rueda P; Delgado Á; Ruiz-Extremera Á; Salmerón J
Liver Int; 2015 Apr; 35(4):1430-41. PubMed ID: 24821649
[TBL] [Abstract][Full Text] [Related]
17. Molecular docking and 3D-QSAR studies on inhibitors of DNA damage signaling enzyme human PARP-1.
Fatima S; Bathini R; Sivan SK; Manga V
J Recept Signal Transduct Res; 2012 Aug; 32(4):214-24. PubMed ID: 22713102
[TBL] [Abstract][Full Text] [Related]
18. Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation.
Halder AK; Saha A; Saha KD; Jha T
J Biomol Struct Dyn; 2015; 33(8):1756-79. PubMed ID: 25350685
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of ( R)-Boc-2-methylproline via a Memory of Chirality Cyclization. Application to the Synthesis of Veliparib, a Poly(ADP-ribose) Polymerase Inhibitor.
Kolaczkowski L; Barkalow J; Barnes DM; Haight A; Pritts W; Schellinger A
J Org Chem; 2019 Apr; 84(8):4837-4845. PubMed ID: 30716275
[TBL] [Abstract][Full Text] [Related]
20. Discovery of the PARP (poly ADP-ribose polymerase) inhibitor 2-(1-(4,4-difluorocyclohexyl)piperidin-4-yl)-1H-benzo[d]imidazole-4-carboxamide for the treatment of cancer.
Tang L; Wu W; Zhang C; Shi Z; Chen D; Zhai X; Jiang Y
Bioorg Chem; 2021 Sep; 114():105026. PubMed ID: 34186467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]